erlotinib hydrochloride has been researched along with beta-elemene in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (beta-elemene) | Trials (beta-elemene) | Recent Studies (post-2010) (beta-elemene) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 258 | 1 | 211 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, XX; Huang, JM; Jiang, ZB; Leung, EL; Nie, XW; Shao, L; Sui, X; Wang, J; Wang, WJ; Wang, XR; Wu, QB; Xie, C; Xie, YJ; Xu, C; Yu, LL; Zhang, RN; Zhang, YZ; Zhao, ZM | 1 |
1 other study(ies) available for erlotinib hydrochloride and beta-elemene
| Article | Year |
|---|---|
β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Ferroptosis; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; RNA, Long Noncoding; Sesquiterpenes | 2023 |